Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Perioperative Opioid Sparing Techniques
Interventions: Intrathecal Morphine Block, Bilateral Quadratus Lumborum Block, Bilateral Transverse Abdominis Plane Block; Procedure
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Oligodendroglioma, Adult
Interventions: Abemaciclib 200 MG; Drug
Lead sponsor: Stephen Bagley, MD, MSCE; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 7 Months
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more

Conditions: Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions: VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000; Biological · Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Placebo, Investigational RSV vaccine MV-012-968 (Dosage 3); Biological · Other
Lead sponsor: Meissa Vaccines, Inc.; Industry
Eligibility: 15 Months to 59 Months
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Norfolk, Nebraska • Omaha, Nebraska • Cincinnati, Ohio

Conditions: Gynecologic Cancers
Interventions: Not listed
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Participants
Interventions: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Infertility, Fertility
Interventions: menotropin, Recominant Follicle Stimulating Hormone (rFSH); Drug
Lead sponsor: Main Line Fertility Center; Other
Eligibility: 21 Years to 38 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 25
States / cities: Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more

Conditions: Healthy Adults
Interventions: Spinal motor evoked responses (sMERs), Continuous stimulation tolerance; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
Interventions: Marizomib, Panobinostat; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab; Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 82 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Erlotinib and Dasatinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced BRAF-mutant Cancers
Interventions: PX-866, vemurafenib; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Tampa, Florida • New York, New York • Philadelphia, Pennsylvania + 2 more

Conditions: Healthy
Interventions: Monovalent Frozen FluMist®, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Submental Laxity
Interventions: Profound System; Device
Lead sponsor: Syneron Medical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: San Mateo, California • San Ramon, California • Alpharetta, Georgia + 2 more

Conditions: Nausea
Interventions: Bremelanotide, Zofran, Placebo; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 644 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 30
States / cities: Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more

Conditions: Bone-Metastatic, Castration-Resistant Prostate Cancer
Interventions: KX2-391; Drug
Lead sponsor: Athenex, Inc.; Industry
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Healthy Volunteer
Interventions: [14C]CC-90001; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Stress, Psychological, Behavioral Symptoms, Sleep, Health Behavior, Weight, Body
Interventions: Meditation, Healthy Eating, Meditation + healthy eating; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV, AIDS, Smoking Cessation
Interventions: Algorithm Treatment, Quitline only; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Aortic Aneurysm, Contrast Induced Nephropathy, Aortic and Arterial Anomalies
Interventions: Low Dose Contrast (Omnipaque) 40mL, Low Dose Contrast (Omnipaque) 50 mL; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy

Abemaciclib in Patients With Oligodendroglioma

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Mono-menotropins Versus rFSH Protocol on Embryo Quality

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Transcutaneous Spinal Cord Stimulation in Healthy Adults

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

Ph I Dasatinib + Erlotinib in Recurrent MG

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

A Clinical Study to Assess the Safety of a New Influenza Vaccine

Treatment With the Profound System for Submental Laxity

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

The Impact of 8 Weeks of Digital Meditation Application and Healthy Eating Program on Work Stress and Health Outcomes

Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study